NEW YORK–(BUSINESS WIRE)–BTIG announced today that it will hold its annual Biotechnology Conference on Monday, August 8th and Tuesday, August 9, 2022, in New York. The firm will host over 125 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include biotech policy … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Vaporizers Market Report 2022, by Type, by Application, by Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The global vaporizers market is expected to grow from $13.05 billion in 2021 to $17.15 billion in 2022 at a compound annual growth rate (CAGR) of 31.4%. The market is expected to reach $44.96 … [Read more…]
NAPA, Calif.–(BUSINESS WIRE)–#CancerResearch—The V Foundation for Cancer Research, a top-rated cancer research charity, announced the 2022 V Foundation Wine Celebration raised more than $6.5 million during a full weekend of events in the Napa Valley, with proceeds supporting early detection research. The 2022 Wine Celebration weekend was hosted by V Foundation Board Member and Duke … [Read more…]
Assay helps detect drug resistant strains of HIV-1 CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics. … [Read more…]
TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus platinum-based chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with disease progression following … [Read more…]
— Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets — — Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage … [Read more…]
Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company … [Read more…]
MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy Global SAFFRON Phase III trial evaluating this combination is underway WILMINGTON, Del.–(BUSINESS WIRE)–Preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an objective response rate (ORR) of 49% (95% confidence interval … [Read more…]
Company Receives FDA Clearance of ALLY™ Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, … [Read more…]
EL DORADO HILLS, Calif.–(BUSINESS WIRE)–#O2Investment–Frontier Dental Lab Group (“Frontier” or “FDL Group”) (www.frontierdentallabgroup.com), a leading dental laboratory platform, announced today that it has partnered with and made an investment in D&S Dental Laboratory, Inc. (“D&S”) (https://dnsdental.com/), a full-service dental laboratory based in Waunakee, WI. Brent West, President of FDL Group, commented, “D&S has an extremely … [Read more…]
